Loading...
Prior to 2021, several sodium–glucose cotransporter (SGLT)-2 inhibitors had been shown to improve cardiovascular (CV) outcomes in patients with heart failure with reduced ejection fraction (HFrEF). In 2021, an industry-funded randomized trial extended these benefits to patients with heart failure and preserved ejection fraction (HFpEF), regardless of diabetes status.
In the EMPEROR-Preserved trial, 6000 patients with class II–IV HFpEF, left ventricular ejection fraction (LVEF) of >40%, and elevated natriuretic peptide levels received the SGLT-2 inhibitor empagliflozin (10 mg daily) or placebo. During median follow-up of 26 months, empagliflozin recipients were significantly less likely than placebo recipients to be hospitalized for HF (8.6% …